| 前收市價 | 34.23 |
| 開市 | 35.68 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 34.95 - 35.84 |
| 52 週波幅 | 23.45 - 37.91 |
| 成交量 | |
| 平均成交量 | 23,250 |
| 市值 | 67.832B |
| Beta 值 (5 年，每月) | 0.26 |
| 市盈率 (最近 12 個月) | 52.16 |
| 每股盈利 (最近 12 個月) | 0.67 |
| 業績公佈日 | 2024年7月29日 - 2024年8月02日 |
| 遠期股息及收益率 | 0.39 (1.13%) |
| 除息日 | 2024年9月27日 |
| 1 年預測目標價 | 35.91 |
BenzingaHeart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million. The company reported an EPS of $0.34, a turnaround from an EPS loss of $(0.79) a year ago, beating the consensus of $0.05. U.S. net product revenue was $24.8 million, up approximately 46% Y/Y. Collaboration revenue was $113.0 million, compared to $7.3 million a year ago, driven by increased tablet sales to international partners and sales growt
Yahoo FinanceAstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
ZacksAtossa (ATOS) Reports Positive Results From EVANGELINE Study
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
